CORD-19:185e78aee848db9cc3a4510619048a6e4acd22cc / 16871-17637
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/185e78aee848db9cc3a4510619048a6e4acd22cc","sourcedb":"CORD-19","sourceid":"185e78aee848db9cc3a4510619048a6e4acd22cc","text":"The high fevers, cardiorespiratory collapse, and neurologic symptoms seen in this series and prior reports are similar to the cytokine release syndrome (CRS) seen following bispecific antibody and chimeric antigen receptor T cell therapy. [22] [23] [24] Multiple cytokines have been implicated in CRS, including interferon-g, IL-10, and IL-6, and monoclonal antibodies targeting the IL-6/IL-6 receptor axis such as tocilizumab are used for CRS treatment, 24, 25 Marked elevation of serum IL-6 was noted in the case report by Suzuki et al, 19 but to our knowledge, tocilizumab has not been used in the context of bleomycin-associated febrile, hypotensive reactions, and in all cases in the present series, symptoms resolved rapidly following corticosteroid treatment.","tracks":[{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T110","span":{"begin":0,"end":766},"obj":"Sentence"}],"attributes":[{"subj":"T110","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T110","span":{"begin":0,"end":766},"obj":"Sentence"},{"id":"TextSentencer_T110","span":{"begin":0,"end":766},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T110","pred":"source","obj":"CORD-19-Sentences"},{"subj":"TextSentencer_T110","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"Epistemic_Statements","denotations":[{"id":"T19","span":{"begin":239,"end":766},"obj":"Epistemic_statement"}],"attributes":[{"subj":"T19","pred":"source","obj":"Epistemic_Statements"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T170","span":{"begin":153,"end":156},"obj":"Disease"},{"id":"T172","span":{"begin":297,"end":300},"obj":"Disease"},{"id":"T174","span":{"begin":440,"end":443},"obj":"Disease"},{"id":"T176","span":{"begin":493,"end":496},"obj":"Disease"}],"attributes":[{"id":"A170","pred":"mondo_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/MONDO_0007399"},{"id":"A171","pred":"mondo_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/MONDO_0017361"},{"id":"A172","pred":"mondo_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/MONDO_0007399"},{"id":"A173","pred":"mondo_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/MONDO_0017361"},{"id":"A174","pred":"mondo_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/MONDO_0007399"},{"id":"A175","pred":"mondo_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/MONDO_0017361"},{"id":"A176","pred":"mondo_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/MONDO_0010518"},{"subj":"T170","pred":"source","obj":"CORD-19-PD-MONDO"},{"subj":"T172","pred":"source","obj":"CORD-19-PD-MONDO"},{"subj":"T174","pred":"source","obj":"CORD-19-PD-MONDO"},{"subj":"T176","pred":"source","obj":"CORD-19-PD-MONDO"}]},{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T57","span":{"begin":482,"end":487},"obj":"Body_part"}],"attributes":[{"id":"A57","pred":"uberon_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"subj":"T57","pred":"source","obj":"CORD-19-PD-UBERON"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19_Custom_license_subset","color":"#ec9393","default":true},{"id":"CORD-19-Sentences","color":"#93acec"},{"id":"Epistemic_Statements","color":"#c6ec93"},{"id":"CORD-19-PD-MONDO","color":"#ec93e0"},{"id":"CORD-19-PD-UBERON","color":"#93ecdd"}]}]}}